Copy to clipboard 
Johnson & Johnson MedTech reported 2Q25 orthopedic sales of $2.3 billion, down -0.3% compared to the second quarter of 2024. For the first half of 2025, the company generated $4.5 billion in orthopedic sales, down -2.3% compared to the prior year.
Competitive pressures, the previously announced restructuring program and volume-based procurement in China drove the declines. The company also faced stiff comparisons from 2024. The second quarter of 2024, for instance, was the third-highest orthopedic revenue quarter for the company in the last ten years.
As J&J MedTech laps those tough comps, it expects to generate momentum with new product launches in key areas where it has faced strong competition.
“While our ortho performance was softer than we would like, we have strong reasons to believe in continued acceleration through the remainder of the year [with] big launches coming our way, especially in the areas where we face the most competition in hips and knees,” said Johnson & Johnson MedTech EVP Tim Schmid. “We have the VELYS Uni Knee, ATTUNE Revision Hinge as well as KINCISE 2.0. And then also in spine, we’re seeing the rollout of our spine VELYS Robot as well as TriALTIS, which we are confident will continue to bolster our growth and competitiveness.”
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $940.3 | $937.9 | $2.4 | 0.3% |
| Knees | $389.1 | $393.5 | ($4.4) | (1.1%) |
| Hips | $420.2 | $416.2 | $4.0 | 1% |
| Extremities | $130.9 | $128.1 | $2.7 | 2.1% |
| Spine | $240.3 | $258.4 | ($18.1) | (7%) |
| Trauma | $684.2 | $675.9 | $8.2 | 1.2% |
| Sports Medicine | $183.6 | $185.7 | ($2.1) | (1.1%) |
| Orthobiologics | $80.7 | $81.7 | ($1.0) | (1.2%) |
| Enabling Technology | $18.2 | $16.3 | $1.8 | 11.2% |
| Other | $157.9 | $156.0 | $1.9 | 1.2% |
| Total | $2,305.1 | $2,312.0 | ($6.9) | (0.3%) |
| 1H25 | 1H24 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,859.6 | $1,884.3 | ($24.6) | (1.3%) |
| Knees | $778.6 | $795.0 | ($16.4) | (2.1%) |
| Hips | $829.4 | $838.6 | ($9.2) | (1.1%) |
| Extremities | $251.6 | $250.7 | $0.9 | 0.4% |
| Spine | $457.5 | $508.1 | ($50.5) | (9.9%) |
| Trauma | $1,369.4 | $1,356.4 | $13.0 | 1% |
| Sports Medicine | $347.9 | $371.8 | ($23.9) | (6.4%) |
| Orthobiologics | $157.8 | $165.9 | ($8.1) | (4.9%) |
| Enabling Technology | $34.3 | $32.1 | $2.1 | 6.7% |
| Other | $319.6 | $333.7 | ($14.1) | (4.2%) |
| Total | $4,546.3 | $4,652.4 | ($106.1) | (2.3%) |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,420.1 | $1,422.8 | ($2.6) | (0.2%) |
| OUS | $885.0 | $889.2 | ($4.2) | (0.5%) |
| EMEA | $429.2 | $426.8 | $2.4 | 0.6% |
| Asia Pacific | $292.0 | $297.9 | ($5.8) | (2%) |
| Rest of World | $163.7 | $164.5 | ($0.8) | (0.5%) |
| Total | $2,305.1 | $2,312.0 | ($6.9) | (0.3%) |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,804.3 | $2,871.0 | ($66.7) | (2.3%) |
| OUS | $1,742.0 | $1,781.4 | ($39.4) | (2.2%) |
| EMEA | $840.6 | $848.4 | ($7.8) | (0.9%) |
| Asia Pacific | $587.7 | $610.1 | ($22.4) | (3.7%) |
| Rest of World | $313.7 | $322.9 | ($9.2) | (2.8%) |
| Total | $4,546.3 | $4,652.4 | ($106.1) | (2.3%) |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $23,743.0 | |
| Cost of Sales | $7,628.0 | 32.1% |
| Selling and Admin | $5,889.0 | 24.8% |
| R & D | $3,516.0 | 14.8% |
| R & D | $3,516.0 | 14.8% |
| Other | $1,173.0 | 4.9% |
Johnson & Johnson MedTech reported 2Q25 orthopedic sales of $2.3 billion, down -0.3% compared to the second quarter of 2024. For the first half of 2025, the company generated $4.5 billion in orthopedic sales, down -2.3% compared to the prior year.
Competitive pressures, the previously announced restructuring program and volume-based...
Johnson & Johnson MedTech reported 2Q25 orthopedic sales of $2.3 billion, down -0.3% compared to the second quarter of 2024. For the first half of 2025, the company generated $4.5 billion in orthopedic sales, down -2.3% compared to the prior year.
Competitive pressures, the previously announced restructuring program and volume-based procurement in China drove the declines. The company also faced stiff comparisons from 2024. The second quarter of 2024, for instance, was the third-highest orthopedic revenue quarter for the company in the last ten years.
As J&J MedTech laps those tough comps, it expects to generate momentum with new product launches in key areas where it has faced strong competition.
“While our ortho performance was softer than we would like, we have strong reasons to believe in continued acceleration through the remainder of the year [with] big launches coming our way, especially in the areas where we face the most competition in hips and knees,” said Johnson & Johnson MedTech EVP Tim Schmid. “We have the VELYS Uni Knee, ATTUNE Revision Hinge as well as KINCISE 2.0. And then also in spine, we’re seeing the rollout of our spine VELYS Robot as well as TriALTIS, which we are confident will continue to bolster our growth and competitiveness.”
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $940.3 | $937.9 | $2.4 | 0.3% |
| Knees | $389.1 | $393.5 | ($4.4) | (1.1%) |
| Hips | $420.2 | $416.2 | $4.0 | 1% |
| Extremities | $130.9 | $128.1 | $2.7 | 2.1% |
| Spine | $240.3 | $258.4 | ($18.1) | (7%) |
| Trauma | $684.2 | $675.9 | $8.2 | 1.2% |
| Sports Medicine | $183.6 | $185.7 | ($2.1) | (1.1%) |
| Orthobiologics | $80.7 | $81.7 | ($1.0) | (1.2%) |
| Enabling Technology | $18.2 | $16.3 | $1.8 | 11.2% |
| Other | $157.9 | $156.0 | $1.9 | 1.2% |
| Total | $2,305.1 | $2,312.0 | ($6.9) | (0.3%) |
| 1H25 | 1H24 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,859.6 | $1,884.3 | ($24.6) | (1.3%) |
| Knees | $778.6 | $795.0 | ($16.4) | (2.1%) |
| Hips | $829.4 | $838.6 | ($9.2) | (1.1%) |
| Extremities | $251.6 | $250.7 | $0.9 | 0.4% |
| Spine | $457.5 | $508.1 | ($50.5) | (9.9%) |
| Trauma | $1,369.4 | $1,356.4 | $13.0 | 1% |
| Sports Medicine | $347.9 | $371.8 | ($23.9) | (6.4%) |
| Orthobiologics | $157.8 | $165.9 | ($8.1) | (4.9%) |
| Enabling Technology | $34.3 | $32.1 | $2.1 | 6.7% |
| Other | $319.6 | $333.7 | ($14.1) | (4.2%) |
| Total | $4,546.3 | $4,652.4 | ($106.1) | (2.3%) |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,420.1 | $1,422.8 | ($2.6) | (0.2%) |
| OUS | $885.0 | $889.2 | ($4.2) | (0.5%) |
| EMEA | $429.2 | $426.8 | $2.4 | 0.6% |
| Asia Pacific | $292.0 | $297.9 | ($5.8) | (2%) |
| Rest of World | $163.7 | $164.5 | ($0.8) | (0.5%) |
| Total | $2,305.1 | $2,312.0 | ($6.9) | (0.3%) |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $2,804.3 | $2,871.0 | ($66.7) | (2.3%) |
| OUS | $1,742.0 | $1,781.4 | ($39.4) | (2.2%) |
| EMEA | $840.6 | $848.4 | ($7.8) | (0.9%) |
| Asia Pacific | $587.7 | $610.1 | ($22.4) | (3.7%) |
| Rest of World | $313.7 | $322.9 | ($9.2) | (2.8%) |
| Total | $4,546.3 | $4,652.4 | ($106.1) | (2.3%) |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $23,743.0 | |
| Cost of Sales | $7,628.0 | 32.1% |
| Selling and Admin | $5,889.0 | 24.8% |
| R & D | $3,516.0 | 14.8% |
| R & D | $3,516.0 | 14.8% |
| Other | $1,173.0 | 4.9% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
